Addressable In‑Vivo Microfluidic Platform for Targeted Biological Manipulation (Addressable Microfluidics Systems and Methods for In Vivo Applications, Tech ID: 23‑005)
Technology Overview: This technology introduces addressable microfluidic systems designed for in‑vivo applications, enabling precise, localized delivery or removal of fluids within living organisms. The platform supports targeted manipulation without disturbing surrounding tissue, allowing dynamic studies of biological systems directly in vivo. This capability is critical for advanced therapeutic delivery, localized diagnostics, and controlled biological experimentation.
Industry Pain Point: Current in‑vivo delivery methods lack precision and often cause unintended systemic effects.
NJIT Solution: This system enables precise, localized microfluidic control within living tissue.
Key Features & Advantages
- Addressable, site‑specific microfluidic control
- Minimally invasive in‑vivo operation
- Reduced systemic exposure
- Adaptable to diagnostics and therapeutics
Development Stage: TRL 3–4 – Early in‑vivo proof‑of‑concept demonstrated.
Target Markets
- Targeted drug delivery
- In‑vivo diagnostics
- Biomedical research platforms
Market Opportunity
- Global targeted drug delivery market (2026): ~$75B
- CAGR: ~8–9%
- Projected market size (2035): ~$145–155B
Commercial & IP Details
Inventors: Anh Tong, Roman Voronov